Bayer-Funded Phase 2 Clinical Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, In Treatment-Resistant Prostate Cancer

You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

This message is from a valued third-party sponsor. It should not be considered a recommendation or endorsement by Benzinga.

Stage 4 prostate cancer has a low survival rate among men, yet the number of cases is projected to increase in the years to come as the population ages. Fighting this form of cancer is imperative, and RedHill Biopharma Ltd.’s (NASDAQ: RDHL) opaganib may provide a new weapon in the seemingly hopeless battle against metastatic castrate-resistant prostate cancer (mCRPC). 

Opaganib, the company’s first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity, has shown promise in the lab in overcoming resistance to the standard of care to treat prostate cancer which is androgen receptor pathway inhibition (ARPI) treatment, the company says.

With the prevalence of prostate cancer set to double over the next 15 years and only a 28% five-year relative survival rate in people with stage 4 prostate cancer, there is a significant need for new approaches in treating mCRPC patients.  

To test its effectiveness further, and supported by Bayer AG (ETR: BAYN)  and the Ramsay Hospital Foundation, RedHill is teaming up with Bayer and leading Australian cancer organizations to launch a phase 2 study combining opaganib with darolutamide, the fastest-growing androgen receptor blocker in the U.S. 

The results of the 80-patient placebo-controlled randomized study could be game-changing for those suffering from prostate cancer and for RedHill. It's a trial investors may want to pay attention to. To learn more about opaganib click here. 

This is a paid ad. Please see 17b disclosure here for more information.